May 17th 2024
Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLC
August 8th 2022Data from the phase 2 NADIM II trial appear to reinforce the superiority of nivolumab and chemotherapy vs chemotherapy alone after the regimen significantly improved overall survival progression-free survival, and pathologic complete response in patients with stage IIIA/B non–small cell lung cancer, according to investigators.
FDA Grants Breakthrough Therapy Designation to Taletrectinib for ROS1+ Non–Small Cell Lung Cancer
August 5th 2022Supported by data from an ongoing phase 2 trial, the ROS1 inhibitor taletrectinib was granted breakthrough therapy designation for the treatment of certain patients with advanced or metastatic ROS1-positive non–small cell lung cancer.
Roy S. Herbst, MD, PhD, Reviews Ramucirumab Plus Pembrolizumab in ICI-Resistant NSCLC
August 3rd 2022At 2022 ASCO, Roy S. Herbst, MD, PhD, spoke about the results of a Lung-MAP substudy showing benefit of ramucirumab plus pembrolizumab vs standard of care chemotherapy for patients with advanced non–small cell lung cancer who demonstrated resistance to prior immunotherapy.
Subcutaneous Vs IV Atezolizumab Demonstrates Non-Inferior Pharmacokinetics in Advanced NSCLC
August 3rd 2022Results from the phase 3 IMscin001 trial indicated that atezolizumab given subcutaneously vs intravenously yielded non-inferior pharmacokinetics for patients with immunotherapy-naïve locally advanced or metastatic non–small cell lung cancer.
Tumor Mutational Burden Associated With Responses, Immune Cell Infiltration in NSCLC
July 10th 2022Those with non–small cell lung cancer who had increasing tumor mutational burden appeared to experience better inflammatory T-cell–mediated responses compared with those who had low tumor mutational burden.
Durvalumab Plus Chemotherapy Yields Statistically Significant Responses in Resectable NSCLC
July 7th 2022Results from the phase 3 AEGEAN trial showed an improved pathological complete response in patients with resectable non–small cell lung cancer treated with durvalumab plus neoadjuvant chemotherapy vs chemotherapy alone.
Promising EFS Noted Following Neoadjuvant Nivo/Chemo in Resectable NSCLC Following pCR
July 1st 2022Patients with stage IB to IIA non–small cell lung cancer who experienced a pathologic complete response to neoadjuvant nivolumab plus platinum-based doublet chemotherapy experienced a prolonged event-free survival.
European Commission Approves Capmatinib in NSCLC With MET Exon 14 Skipping Mutation
June 22nd 2022Based on results from the phase 2 GEOMETRY mono-1 trial, the European Commission has approved capmatinib for patients with non–small cell lung cancer who have MET exon 14 skipping mutations, and a need for systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
UK’s MHRA Accepts Marketing Authorization Application for Aumolertinib in EGFR+ Advanced NSCLC
June 21st 2022Results from the phase 3 AENA trial led to the United Kingdom’s Medicine and Healthcare products Regulatory Agency accepting a marketing authorization application for aumolertinib for review in patients with locally advanced or metastatic non–small cell lung cancer with activating EGFR mutations, and those with locally advanced or metastatic EGFR T790M mutation–positive non–small cell lung cancer.